Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy

Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy on 1.5T T2*-Weighted Imaging

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05394636

Acronym

CSS

Enrollment

111

Registered

2022-05-27

Start date

2022-06-01

Completion date

2022-12-31

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Amyloid Angiopathy, Siderosis

Brief summary

Cerebellar superficial siderosis (SS) has been recently reported to be present in about 10% of both hereditary (n=50) and sporadic (n=46) cerebral amyloid angiopathy (CAA) patients on 3T MRI using susceptibility-weighted imaging (SWI) in the majority of patients. In that study, cerebellar SS was associated with a higher number of supratentorial lobar and superficial cerebellar macrobleeds (although cerebellar SS was not directly located adjacent to these cerebellar macrobleeds). It is unclear if cerebellar SS is caused by in situ leakage of cerebellar leptomeningeal vessels or rather represents hemorrhagic diffusion from cerebellar parenchymal micro/macrobleeds or from supratentorial bleeding sources via the tentorium cerebelli (TC).

Interventions

OTHERNone, pure observational study

None, pure observational study

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CAA patients (according to the modified Boston criteria) * with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS

Exclusion criteria

* Patients with recent trauma, * Patients with anticoagulation treatment, * Patients with pathological blood coagulation tests (activated partial thromboplastin time \[aPTT\] ratio=patient's aPTT/normal control aPTT\] \>1.2; or partial thromboplastin time \[PTT\] \<75%) or platelet count (\<100 x 109/L) * Patients with inflammatory CAA

Design outcomes

Primary

Measure	Time frame	Description
MRI analyse : presence of cerebellar SS	baseline	presence of cerebellar SS (Yes/No)
MRI analyse : Location of cerebellar SS	baseline	Location of cerebellar SS (vermis, anterior lobe, posterior lobe)
MRI analyse : characteristics of cerebellar SS	baseline	number of cerebellar sulci involved
MRI analyse : Presence of cerebellar macrobleeds	baseline	Presence of cerebellar macrobleeds (Yes/No)
MRI analyse : Presence of cerebral macrobleeds	baseline	Presence of cerebral macrobleeds (Yes/No)
MRI analyse : Characteristics of cerebral macrobleeds	baseline	spatial relationship of cerebral macrobleeds with the TC \[adjacent vs. non-adjacent to TC\]
MRI analyse : Characteristics of cortical SS	baseline	spatial relationship with TC (adjacent vs. non-adjacent to TC)
MRI analyse : hemosiderin	baseline	presence of hemosiderin deposition along the TC.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026